04380nam 2200805 450 991027974600332120180731045016.02-7606-2944-9979-1-03-650453-22-7606-2402-110.4000/books.pum.13708(CKB)2470000000002200(EBL)3248957(SSID)ssj0000734468(PQKBManifestationID)11483179(PQKBTitleCode)TC0000734468(PQKBWorkID)10722202(PQKB)10488819(MiAaPQ)EBC4750261(CaPaEBR)406445(CaBNvSL)slc00207739(MiAaPQ)EBC3248957(FrMaCLE)OB-pum-13708(oapen)https://directory.doabooks.org/handle/20.500.12854/40513(PPN)230002331(VaAlCD)20.500.12592/f87zq6(schport)gibson_crkn/2009-12-01/3/406445(EXLCZ)99247000000000220020161213h20032003 uy 0freur|n|---|||||txtccrL'aide au conditionnel la contrepartie dans les mesures envers les personnes sans emploi en Europe et en Amérique du Nord /Pascale Dufour, Gérard Boismenu, Alain NoelPresses de l’Université de Montréal2003[Montréal, Quebećbec] :Les Presses de l'Université de Montréal,2003.©20031 online resource (251 p.)Politique et EconomieDescription based upon print version of record.2-7606-1880-3 Includes bibliographical references.Les politiques de soutien qui visent les sans-emploi sont de plus en plus souvent assorties de conditions que l'on regroupe sous le terme de contrepartie. Ces politiques dites « actives » font appel à la responsabilité des personnes et imposent des conditions plus ou moins contraignantes. Parallèlement, l'aide tend à devenir moins généreuse. Ce livre étudie la transformation de ces politiques dans six pays : le Canada, les États-Unis, le Royaume-Uni, la France, l'Allemagne et le Danemark. Cette étude comparative transversale fait ressortir les relations entre les sans-emploi et l'État, le marché du travail et l'environnement social. La contrepartie témoigne de la transformation de l'action sociale des États. La situation varie beaucoup d'un pays à l'autre, et ces différences sont révélatrices de tendances plus larges à l'oeuvre dans les politiques sociales. On trouve d'un côté des pays qui organisent le traitement des sans-emploi sous un mode plutôt collectif et de l'autre, des pays où l'individu et la sanction du marché constituent la référence première. Par ailleurs, si l'intervention de l'État passe de plus en plus par un soutien aux familles, celui-ci varie beaucoup au point d'apparaître comme la dimension la plus discriminante des nouvelles politiques sociales. Ce livre propose une analyse systématique des logiques d'intervention qui façonnent ces nouvelles formes de protection sociale. Il s'adresse non seulement aux chercheurs, mais aussi aux professionnels qui interviennent auprès des personnes sans emploi et aux décideurs.Politique et économie.Unemployment insuranceGovernment policyUnemployment insurance claimantsEmploymentUnemployment insuranceSocial aspectsUnemployment insuranceGovernment policyEuropeUnemployment insuranceGovernment policyNorth Americachômageprotection socialeÉtat providencesans-emploiUnemployment insuranceGovernment policy.Unemployment insurance claimantsEmployment.Unemployment insuranceSocial aspects.Unemployment insuranceGovernment policyUnemployment insuranceGovernment policy353.5/4Dufour Pascale1971-956729Boismenu GérardNoël AlainMiAaPQMiAaPQMiAaPQBOOK9910279746003321L'aide au conditionnel2166738UNINA06341nam 22009733u 450 991013955570332120260217225553.01-283-24049-197866132404911-4443-4257-61-4443-4254-1(CKB)2550000000045840(EBL)819297(OCoLC)759159254(SSID)ssj0000633398(PQKBManifestationID)12245060(PQKBTitleCode)TC0000633398(PQKBWorkID)10619848(PQKB)11067818(MiAaPQ)EBC819297(EXLCZ)99255000000004584020131104d2011|||| u|| |engur|n|---|||||txtccrClinical Dilemmas in Inflammatory Bowel Disease New Challenges2nd ed.Hoboken Wiley20111 online resource (286 p.)Description based upon print version of record.1-4443-3454-9 Clinical Dilemmas inInflammatoryBowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD-Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD-passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment8 Prebiotics and synbiotics: panacea or placebo9 Worms: light at the end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids17 Steroids in Crohn's disease: do the benefits outweigh the dangers?Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use?26 What is the role of biologics in UC?27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis?35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease41 Does anti-TNF therapy increase the risk of complications of surgery?The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinkingClinical dilemmasInflammatory bowel diseasesInflammatory Bowel DiseasesInflammatory bowel diseases - Decision makingInflammatory bowel diseases -- Decision makingInflammatory bowel diseasesDecision makingInflammatory bowel diseasesIntestinal DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesDiseaseInflammatory Bowel DiseasesMedicineHILCCHealth & Biological SciencesHILCCGastroenterologyHILCCClinical dilemmas.Inflammatory bowel diseases.Inflammatory Bowel Diseases.Inflammatory bowel diseases - Decision making.Inflammatory bowel diseases -- Decision making.Inflammatory bowel diseasesDecision making.Inflammatory bowel diseases.Intestinal Diseases.Gastroenteritis.Gastrointestinal Diseases.Digestive System Diseases.Disease.Inflammatory Bowel Diseases.MedicineHealth & Biological SciencesGastroenterology616.344Irving Peter1970-909420Siegel Corey A956257Rampton David457140Shanahan Fergus909421AU-PeELAU-PeELAU-PeELBOOK9910139555703321Clinical Dilemmas in Inflammatory Bowel Disease4543238UNINA